Does Managed Care Affect the Diffusion of Psychotropic Medications?

Overview

Journal Health Econ

Publisher Wiley

Specialties Health Services
Public Health

Date 2011 Mar 9

PMID 21384465

Citations 3

Authors

Marisa E Domino

Affiliations

Soon will be listed here.

Abstract

Newer technologies to treat many mental illnesses have shown substantial heterogeneity in diffusion rates across states. In this paper, I investigate whether variation in the level of managed care penetration is associated with changes in state-level diffusion of three newer classes of psychotropic medications in fee-for-service Medicaid programs from 1991 to 2005. Three different types of managed care programs are examined: capitated managed care, any type of managed care and behavioral health carve-outs. A fourth-order polynomial fixed effect regression model is used to model the diffusion path of newer antidepressant and antipsychotic medications controlling for time-varying state characteristics. Substantial differences are found in the diffusion paths by the degree of managed care use in each state Medicaid program. The largest effect is seen through spillover effects of capitated managed care programs; states with greater capitated managed care have greater initial shares of newer psychotropic medications. The influence of carve-outs and of all types of managed care combined on the diffusion path was modest.

Citing Articles

Comparing Adoption of Breakthrough and "Me-too" Drugs among Medicare Beneficiaries: A Case Study of Dipeptidyl Peptidase-4 Inhibitors.

Hernandez I, Zhang Y J Pharm Innov. 2017; 12(2):105-109.

PMID: 28966696 PMC: 5614454. DOI: 10.1007/s12247-017-9277-x.

State Investments in Psychiatric Innovation: Investigating Unmeasured State Factors.

Domino M, Beadles C Health Serv Outcomes Res Methodol. 2014; 14(1-2):34-53.

PMID: 25395878 PMC: 4226516. DOI: 10.1007/s10742-014-0116-y.

Public managed care and service access in outpatient substance abuse treatment units.

Chuang E, Wells R, Alexander J J Behav Health Serv Res. 2010; 38(4):444-63.

PMID: 21184286 DOI: 10.1007/s11414-010-9230-y.

References

Goldman D, Smith J . Socioeconomic Differences in the Adoption of New Medical Technologies. Am Econ Rev. 2017; 95(2):234-7. DOI: 10.1257/000282805774669907. View

Baker L . Association of managed care market share and health expenditures for fee-for-service Medicare patients. JAMA. 1999; 281(5):432-7. DOI: 10.1001/jama.281.5.432. View

Bradley C . Decision making and prescribing patterns--a literature review. Fam Pract. 1991; 8(3):276-87. DOI: 10.1093/fampra/8.3.276. View

Frank R, Zeckhauser R . Custom-made versus ready-to-wear treatments: behavioral propensities in physicians' choices. J Health Econ. 2007; 26(6):1101-27. DOI: 10.1016/j.jhealeco.2007.08.002. View

Ellison S, Cockburn I, Griliches Z, Hausman J . Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. Rand J Econ. 2002; 28(3):426-46. View

Hemminki E . Review of literature on the factors affecting drug prescribing. Soc Sci Med (1967). 1975; 9(2):111-6. DOI: 10.1016/0037-7856(75)90103-1. View

Grazier K, Eselius L, Hu T, Shore K, GSell W . Effects of a mental health carve-out on use, costs, and payers: a four-year study. J Behav Health Serv Res. 1999; 26(4):381-9. DOI: 10.1007/BF02287299. View

Rahme D, Ayoub M, Shaito K, Saleh N, Assaf S, Lahoud N . First trend analysis of antifungals consumption in Lebanon using the World Health Organization collaborating center for drug statistics methodology. BMC Infect Dis. 2022; 22(1):882. PMC: 9700908. DOI: 10.1186/s12879-022-07883-5. View

Mas N, Seinfeld J . Is managed care restraining the adoption of technology by hospitals?. J Health Econ. 2008; 27(4):1026-1045. DOI: 10.1016/j.jhealeco.2008.02.009. View

10.

Peay M, Peay E . Innovation in high risk drug therapy. Soc Sci Med. 1994; 39(1):39-52. DOI: 10.1016/0277-9536(94)90164-3. View

11.

Crystal S, Sambamoorthi U, Merzel C . The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Health Serv Res. 1995; 30(4):593-614. PMC: 1070077. View

12.

Barrett B, Byford S, Knapp M . Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord. 2004; 84(1):1-13. DOI: 10.1016/j.jad.2004.10.003. View

13.

Domino M, Salkever D . Price elasticity and pharmaceutical selection: the influence of managed care. Health Econ. 2003; 12(7):565-86. DOI: 10.1002/hec.743. View

14.

Frank R, Huskamp H, McGuire T, NEWHOUSE J . Some economics of mental health 'carve-outs'. Arch Gen Psychiatry. 1996; 53(10):933-7. DOI: 10.1001/archpsyc.1996.01830100081010. View

15.

Weiss R, Charney E, Baumgardner R, German P, Mellits E, Skinner E . Changing patient management: what influences the practicing pediatrician?. Pediatrics. 1990; 85(5):791-5. View

16.

Huskamp H . Episodes of mental health and substance abuse treatment under a managed behavioral health care carve-out. Inquiry. 1999; 36(2):147-61. View

17.

Wells K, Burnam M . Caring for depression in America: lessons learned from early findings of the medical outcomes study. Psychiatr Med. 1991; 9(4):503-19. View

18.

Weiner J, Lyles A, Steinwachs D, Hall K . Impact of managed care on prescription drug use. Health Aff (Millwood). 1991; 10(1):140-54. DOI: 10.1377/hlthaff.10.1.140. View

19.

Christensen D, Bush P . Drug prescribing: patterns, problems and proposals. Soc Sci Med A. 1981; 15(3 Pt 2):343-55. DOI: 10.1016/0271-7123(81)90065-1. View

20.

Berndt E, Bhattacharjya A, Mishol D, Arcelus A, Lasky T . An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts. J Ment Health Policy Econ. 2003; 5(1):3-19. View